Company: ZVRA
Filing Date: 2025-03-31
Form Type: PREC14A
Source: 0001193125-25-068746
Chunk: 68

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: PREC14A
Chunk 68
---
 — |     |                                  — |     |                           — |     |                                 1,982,865 |     |                          1,837,951 |     |                              95.75 |     | -105,511,000 |
| 2023 |     |                          3,445,231 |     |                   4,975,770 |     |                          3,593,438 |     |                   4,385,998 |     |                          4,122,558 |     |                   3,308,589 |     |                          1,669,956 |     |                   2,211,127 |     |                                 2,039,861 |     |                          2,724,999 |     |                              75.20 |     |  -46,049,000 |
| 2022 |     |                                  — |     |                           — |     |                          2,400,356 |     |                   1,349,703 |     |                                  — |     |                           — |     |                                  — |     |                           — |     |                                 1,199,492 |     |                          1,106,040 |     |                              52.70 |     |  -26,772,000 |

| (1) | Mr. McFarlanebecame our Chief Executive Officer on October 10, 2023. |

| (2) | Dr. Travis Mickleserved as the Company’s Chief Executive Officer in 2022 and from January 1, 2023 until January 6, 2023. |

| (3) | Mr. Pascoeserved as the Company’s Chief Executive Officer from January 6, 2023 until June 1, 2023. As noted below, Mr. Pascoe also served as anon-PEONEO in 2022, and his compensation for that year is reflected in the columns entitled “Average Summary Compensation Table Total forNon-PEONEOs” and “Average Compensation Actually Paid toNon-PEONEOs.” |

| (4) | Ms. Christal Mickleserved as the Company’s Interim Chief Executive Officer from June 1, 2023 until October 10, 2023. |

| (5) | Amounts represent the average compensation actually paid to our remaining named executive officers for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated below for each fiscal year. |